Orion Biotech Opportunities Corp. Class A Ordinary Share
ORIA
ORIA was delisted on the 28th of April, 2023.
51 hedge funds and large institutions have $149M invested in Orion Biotech Opportunities Corp. Class A Ordinary Share in 2022 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 11 increasing their positions, 6 reducing their positions, and 6 closing their positions.
83% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 6
4% more capital invested
Capital invested by funds: $142M → $149M (+$6.21M)
2% less funds holding
Funds holding: 52 → 51 (-1)
17% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCL
Glazer Capital LLC
New York
|
+$3.81M |
| 2 |
Jane Street
New York
|
+$3.69M |
| 3 |
AC
Aristeia Capital
Greenwich,
Connecticut
|
+$1.52M |
| 4 |
FTCM
First Trust Capital Management
Chicago,
Illinois
|
+$901K |
| 5 |
Millennium Management
New York
|
+$675K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HighTower Advisors
Chicago,
Illinois
|
-$3.86M |
| 2 |
UOC
UBS O'Connor
Chicago,
Illinois
|
-$2.34M |
| 3 |
CCM
Context Capital Management
Lajolla,
California
|
-$1.04M |
| 4 |
CF
Cantor Fitzgerald
New York
|
-$999K |
| 5 |
AFM
Anson Funds Management
Dallas,
Texas
|
-$738K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
UOC
51
UBS O'Connor
Chicago,
Illinois
| – | -$2.34M | -237,693 | Closed |
|
|
CCM
52
Context Capital Management
Lajolla,
California
| – | -$1.04M | -105,800 | Closed |
|
|
AFM
53
Anson Funds Management
Dallas,
Texas
| – | -$738K | -75,000 | Closed |
|
54
Bank of Montreal
Toronto,
Ontario, Canada
| – | -$329 | -33,396 | Closed |
|
55
D.E. Shaw & Co
New York
| – | -$249K | -25,301 | Closed |
|
|
WAM
56
Wolverine Asset Management
Chicago,
Illinois
| – | -$23K | -2,369 | Closed |
|
|
CS
57
Clear Street
New York
| – | +$60 | +6 | New |
|
ORIA Hedge Fund Activity: Q4 2022 in Review
51 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Orion Biotech Opportunities Corp. Class A Ordinary Share (ORIA) for Q4 2022, worth a combined $149M — up 4.4% from $142M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of ORIA and 5 opened new positions — a net loss of 1 holder — while 6 trimmed existing stakes and 11 added.
The largest buyer was Glazer Capital LLC, adding an estimated $3.81M. The largest seller was HighTower Advisors, cutting an estimated $3.86M.
- 51 institutional investors held Orion Biotech Opportunities Corp. Class A Ordinary Share (ORIA) as of Q4 2022, down from 52 in Q3 2022.
- Funds reported $149M of Orion Biotech Opportunities Corp. Class A Ordinary Share stock for Q4 2022, up 4.4% quarter-over-quarter.
- 5 funds opened new Orion Biotech Opportunities Corp. Class A Ordinary Share positions in Q4 2022 and 6 closed out, a net change of -1 holder.
- The largest Orion Biotech Opportunities Corp. Class A Ordinary Share buyer in Q4 2022 was Glazer Capital LLC, an estimated $3.81M added.
- The largest Orion Biotech Opportunities Corp. Class A Ordinary Share seller in Q4 2022 was HighTower Advisors, an estimated $3.86M sold.
Based on aggregated 13F filings for Q4 2022.